Buscar
Mostrando ítems 1-10 de 11
Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy
(Taylor & Francis, 2019-01-03)
[Abstract] OBJECTIVES: Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in ...
Influence of drug–drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus
(BMJ, 2019-06-13)
[Abstract] Objectives Direct-acting antivirals are the recommended treatment for hepatitis C-infected patients. Drug–drug interactions with concomitant treatments can cause lack of effectiveness and/or safety. The objective ...
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
(Wiley, 2018-11-02)
[Abstract] Two elvitegravir/cobicistat‐based therapies combined with emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) or emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) are currently available for ...
Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors
(Wiley, 2016-06-06)
[Abstract] The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period ...
Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients
(Elsevier, 2017-01-18)
[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated.
Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have ...
Effectiveness and Safety of Direct‐Acting Antivirals in Hepatitis C Infected Patients With Mental Disorders: Results in Real Clinical Practice
(Willey Online Library, 2020-03-17)
[Abstract]
The aim of this study is to analyze the effectiveness and safety of direct‐acting antivirals (DAAs) in psychiatric patients with chronic hepatitis C (CHC). Secondary objectives included adherence and drug‐drug ...
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients: results in real clinical practice
(Sociedad Española de Quimioterapia, 2019)
[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this ...
Effectiveness and Safety of Sofosbuvir/Velpatasvir ± Ribavirin vs Glecaprevir/Pibrentasvir in Genotype 3 Hepatitis C Virus Infected Patients
(BMJ Publishing Group, 2020-02-07)
[Abstract]
Objectives. Sofosbuvir/velpatasvir±ribavirin (SOF/VEL±RBV) and glecaprevir/pibrentasvir (GLE/PIB) are the drug combinations of choice for treating individuals with genotype 3 hepatitis C virus (G3-HCV) infection. ...
Late HIV diagnosis but earlier antiretroviral treatment initiation in northwest Spain: impact of current treatment guidelines
(Sage, 2019-01-10)
[Abstract] Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) initiation for all HIV-infected individuals regardless of CD4 count. This study evaluates the immunological and virological ...
Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
(Plos ONE, 2019-06-03)
[Abstract] BACKGROUND:
Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular ...